Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, NRB7, Boston, MA 02115, USA.
Circulation. 2011 Dec 20;124(25):2920-32. doi: 10.1161/CIRCULATIONAHA.110.009910. Epub 2011 Dec 5.
BACKGROUND: The calcium-binding proteins myeloid-related protein (MRP)-8 (S100A8) and MRP-14 (S100A9) form MRP-8/14 heterodimers (S100A8/A9, calprotectin) that regulate myeloid cell function and inflammatory responses and serve as early serum markers for monitoring acute allograft rejection. Despite functioning as a proinflammatory mediator, the pathophysiological role of MRP-8/14 complexes in cardiovascular disease is incompletely defined. This study investigated the role of MRP-8/14 in cardiac allograft rejection using MRP-14(-/-) mice that lack MRP-8/14 complexes. METHODS AND RESULTS: We examined parenchymal rejection after major histocompatibility complex class II allomismatched cardiac transplantation (bm12 donor heart and B6 recipients) in wild-type (WT) and MRP-14(-/-) recipients. Allograft survival averaged 5.9±2.9 weeks (n=10) in MRP-14(-/-) recipients compared with >12 weeks (n=15; P<0.0001) in WT recipients. Two weeks after transplantation, allografts in MRP-14(-/-) recipients had significantly higher parenchymal rejection scores (2.8±0.8; n=8) than did WT recipients (0.8±0.8; n=12; P<0.0001). Compared with WT recipients, allografts in MRP-14(-/-) recipients had significantly increased T-cell and macrophage infiltration and increased mRNA levels of interferon-γ and interferon-γ-associated chemokines (CXCL9, CXCL10, and CXCL11), interleukin-6, and interleukin-17 with significantly higher levels of Th17 cells. MRP-14(-/-) recipients also had significantly more lymphocytes in the adjacent para-aortic lymph nodes than did WT recipients (cells per lymph node: 23.7±0.7×10(5) for MRP-14(-/-) versus 6.0±0.2×10(5) for WT; P<0.0001). The dendritic cells (DCs) of the MRP-14(-/-) recipients of bm12 hearts expressed significantly higher levels of the costimulatory molecules CD80 and CD86 than did those of WT recipients 2 weeks after transplantation. Mixed leukocyte reactions with allo-endothelial cell-primed MRP-14(-/-) DCs resulted in significantly higher antigen-presenting function than reactions using WT DCs. Ovalbumin-primed MRP-14(-/-) DCs augmented proliferation of OT-II (ovalbumin-specific T cell receptor transgenic) CD4(+) T cells with increased interleukin-2 and interferon-γ production. Cardiac allografts of B6 major histocompatibility complex class II(-/-) hosts and of B6 WT hosts receiving MRP-14(-/-) DCs had significantly augmented inflammatory cell infiltration and accelerated allograft rejection compared with WT DCs from transferred recipient allografts. Bone marrow-derived MRP-14(-/-) DCs infected with MRP-8 and MRP-14 retroviral vectors showed significantly decreased CD80 and CD86 expression compared with controls, indicating that MRP-8/14 regulates B7-costimulatory molecule expression. CONCLUSIONS: Our results indicate that MRP-14 regulates B7 molecule expression and reduces antigen presentation by DCs and subsequent T-cell priming. The absence of MRP-14 markedly increased T-cell activation and exacerbated allograft rejection, indicating a previously unrecognized role for MRP-14 in immune cell biology.
背景:钙结合蛋白髓系相关蛋白(MRP)-8(S100A8)和 MRP-14(S100A9)形成 MRP-8/14 异二聚体(S100A8/A9,钙卫蛋白),调节髓系细胞功能和炎症反应,并作为监测急性同种异体移植排斥反应的早期血清标志物。尽管作为一种促炎介质,但 MRP-8/14 复合物在心血管疾病中的病理生理作用尚不完全明确。本研究使用缺乏 MRP-8/14 复合物的 MRP-14(-/-) 小鼠研究了 MRP-8/14 在心脏同种异体移植排斥中的作用。
方法和结果:我们在主要组织相容性复合物 II 错配的心脏移植(bm12 供体心脏和 B6 受体)后检查实质排斥反应(bm12 供体心脏和 B6 受体)在野生型(WT)和 MRP-14(-/-) 受体中。与 WT 受体(>12 周,n=15;P<0.0001)相比,MRP-14(-/-) 受体的同种异体移植物平均存活时间为 5.9±2.9 周(n=10)。移植后 2 周,MRP-14(-/-) 受体的同种异体移植物实质排斥评分(2.8±0.8;n=8)明显高于 WT 受体(0.8±0.8;n=12;P<0.0001)。与 WT 受体相比,MRP-14(-/-) 受体的同种异体移植物中 T 细胞和巨噬细胞浸润明显增加,干扰素-γ 和干扰素-γ 相关趋化因子(CXCL9、CXCL10 和 CXCL11)、白细胞介素-6 和白细胞介素-17 的 mRNA 水平明显升高,Th17 细胞水平明显升高。MRP-14(-/-) 受体的相邻腹主动脉淋巴结中的淋巴细胞也明显多于 WT 受体(每淋巴结细胞数:MRP-14(-/-)为 23.7±0.7×10(5),WT 为 6.0±0.2×10(5);P<0.0001)。移植后 2 周,bm12 心脏的 MRP-14(-/-) 受体的树突状细胞(DC)表达的共刺激分子 CD80 和 CD86 水平明显高于 WT 受体。用同种内皮细胞致敏的 MRP-14(-/-) DC 进行混合白细胞反应导致抗原呈递功能明显高于用 WT DC 进行的反应。卵清蛋白致敏的 MRP-14(-/-) DC 增强了 OT-II(卵清蛋白特异性 T 细胞受体转基因)CD4(+)T 细胞的增殖,并增加了白细胞介素-2 和干扰素-γ 的产生。与 WT DC 相比,B6 主要组织相容性复合物 II(-/-) 宿主的心脏同种异体移植物和接受 MRP-14(-/-) DC 的 B6 WT 宿主的心脏同种异体移植物的炎症细胞浸润明显增加,同种异体移植物排斥加速。用 MRP-8 和 MRP-14 逆转录病毒载体感染骨髓源性 MRP-14(-/-) DC 后,CD80 和 CD86 的表达明显降低,表明 MRP-8/14 调节 B7 共刺激分子的表达。
结论:我们的结果表明,MRP-14 调节 B7 分子的表达,降低 DC 的抗原呈递能力,并随后引发 T 细胞的初始激活。MRP-14 的缺失显著增加了 T 细胞的激活,并加剧了同种异体移植物排斥反应,表明 MRP-14 在免疫细胞生物学中具有以前未被认识到的作用。
Circulation. 2011-12-5
Circulation. 2008-4-15
Mol Biomed. 2025-8-29
Int J Mol Sci. 2020-11-13
Front Immunol. 2018-6-11
Front Immunol. 2016-4-26
Nat Rev Nephrol. 2016-5
Transplantation. 2011-1-15
Circulation. 2008-4-15